Radical cystectomy for invasive bladder cancer: long-te

World Journal of Urology
24, 296-304
DOI: 10.1007/s00345-006-0061-7

Citation Report

#	Article	IF	Citations
1	Chemotherapy practices and perspectives in invasive bladder cancer. Expert Review of Anticancer Therapy, 2006, 6, 1473-1482.	1.1	2
2	Prostate-sparing cystectomy: has Pandoraâ€™s box been opened?. Expert Review of Anticancer Therapy, 2007, 7, 1003-1014.	1.1	12
3	Treatment of muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1279-1283.	1.1	24
4	Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis, 2007, 28, 1745-1751.	1.3	75
5	Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Current Opinion in Urology, 2007, 17, 369-375.	0.9	93
6	Pathological Guidelines for Orthotopic Urinary Diversion in Women With Bladder Cancer: A Review of the Literature. Journal of Urology, 2007, 178, 756-760.	0.2	69
8	Clinicopathologic Features of Prostate Adenocarcinoma Incidentally Discovered at the Time of Radical Cystectomy: An Evidence-Based Analysis. European Urology, 2007, 52, 648-657.	0.9	75
9	Evaluation of laparoscopic radical cystectomy for loco-regionally advanced bladder cancer. World Journal of Urology, 2008, 26, 161-166.	1.2	13
10	Bladderâ€sparing, combinedâ€modality approach for muscleâ€invasive bladder cancer. Cancer, 2008, 112, 75-83.	2.0	83
11	The origins of bladder cancer. Laboratory Investigation, 2008, 88, 686-693.	1.7	52
12	Current status of prostate-sparing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 486-493.	0.8	19
13	La cistectomia ieri come oggi?. Urologia, 2008, 75, 124-126.	0.3	0
14	The Oncologic and Functional Results of the Ileal W-neobladder with a Serous-lined Extramural Tunnel. Korean Journal of Urology, 2008, 49, 797.	0.2	1
15	Robotic Cystectomy. Scandinavian Journal of Surgery, 2009, 98, 89-95.	1.3	29
16	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology, 2009, 27, 5680-5684.	0.8	56
17	Review: Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome. Therapeutic Advances in Urology, 2009, 1, 43-50.	0.9	9
18	Pathology of the prostate in radical cystectomy specimens: A critical review. Surgical Oncology, 2009, 18, 73-84.	0.8	22
19	Pelvic lymph node dissection and outcome of robot-assisted radical cystectomy for bladder carcinoma. Journal of Robotic Surgery, 2009, 3, 7-12.	1.0	11

#	Article	IF	Citations
20	The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World Journal of Urology, 2009, 27, 33-38.	1.2	54
21	Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostateâ€specific antigen level. Cancer Science, 2009, 100, 1880-1884.	1.7	15
22	Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU International, 2009, 104, 1227-1232.	1.3	64
23	Optimizing outcomes at every stage of bladder cancer: Do we practice it?. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 72-74.	0.8	16
24	Management of Bladder Cancer. Drugs, 2009, 69, 1173-1187.	4.9	15
25	CistoprostatectomÃa radical con preservaciÃ³n neurovascular para el tratamiento del cÃ¡ncer vesical. RelaciÃ³n con la disfunciÃ³n erÃ©ctil: revisiÃ³n de la literatura cientÃfica. Revista Internacional De AndrologÃa, 2009, 7, 121-130.	0.1	0
26	Surgical Apgar Outcome Score: Perioperative Risk Assessment for Radical Cystectomy. Journal of Urology, 2009, 181, 1046-1053.	0.2	77
27	Treatment Results of Radiation Therapy for Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2010, 186, 203-209.	1.0	16
28	Radical cystectomy in the elderly patient: a contemporary comparison of perioperative complications in a single institution series. World Journal of Urology, 2010, 28, 445-450.	1.2	29
29	Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept. European Urology, 2010, 58, 105-111.	0.9	27
30	Matrix metalloproteinaseâ€7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Science, 2010, 101, 1300-1308.	1.7	92
31	Incidental prostate cancer at radical cystoprostatectomy: implications for apexâ€sparing surgery. BJU International, 2010, 105, 468-471.	1.3	39
32	Evidenceâ€based clinical practice guidelines for bladder cancer (Summary â€“ JUA 2009 Edition). International Journal of Urology, 2010, 17, 102-124.	0.5	21
33	Functional outcome of orthotopic bladder substitution: A comparison between the S-shaped and U-shaped neobladder. Scandinavian Journal of Urology and Nephrology, 2010, 44, 197-203.	1.4	4
35	Developing Selection Criteria for Prostate-sparing Cystectomy: A Review of Cystoprostatectomy Specimens. Urology, 2010, 75, 1116-1120.	0.5	22
36	Robot Assisted Laparoscopic Pelvic Lymphadenectomy at the Time of Radical Cystectomy Rivals That of Open Surgery: Single Institution Report. Urology, 2010, 76, 1400-1404.	0.5	60
37	Radical Cystectomy in Patients Previously Treated for Localized Prostate Cancer. Urology, 2010, 76, 1430-1433.	0.5	15
38	Robotic Partial Cystectomy for Bladder Cancer: A Single-Institutional Pilot Study. Journal of Endourology, 2010, 24, 223-227.	1.1	35

#	Article	IF	Citations
39	Practical Urology: Essential Principles and Practice. , 2011, , .		14
41	Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens. World Journal of Surgical Oncology, 2011, 9, 81.	0.8	12
42	Robotic-assisted reconstructive urology. Current Opinion in Urology, 2011, 21, 483-487.	0.9	0
43	Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 908-914.	0.6	29
44	Morbidity and Quality of Life in Bladder Cancer Patients following Cystectomy and Urinary Diversion: A Single-Institution Comparison of Ileal Conduit versus Orthotopic Neobladder. ISRN Urology, 2012, 2012, 1-8.	1.5	58
45	Current and Emerging Strategies in Bladder Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 589-603.	0.9	15
46	Characteristics of Lymph Node Metastases Defining the Outcome After Radical Cystectomy of Urothelial Bladder Carcinoma. Japanese Journal of Clinical Oncology, 2012, 42, 1066-1072.	0.6	8
47	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. British Journal of Cancer, 2012, 106, 1187-1195.	2.9	17
48	Incidentally Found Prostate Cancer and Influence on Overall Survival after Radical Cystoprostatectomy. Prostate Cancer, 2012, 2012, 1-5.	0.4	13
49	Bladder Cancer: A Simple Model Becomes Complex. Current Genomics, 2012, 13, 395-415.	0.7	29
50	Bladder Cancer and Stem Cells. Current Signal Transduction Therapy, 2012, 7, 209-219.	0.3	0
51	Radical cystectomy with orthotopic neobladder reconstruction following prior radical prostatectomy. World Journal of Urology, 2012, 30, 741-745.	1.2	13
52	Robotic Urologic Surgery. , 2012, , .		4
53	Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. Urology, 2012, 80, 737.e13-737.e18.	0.5	12
55	High insulinâ€like growth factor mRNAâ€binding protein 3 (IMP3) protein expression is associated with poor survival in muscleâ€invasive bladder cancer. BJU International, 2012, 110, E308-17.	1.3	31
57	Impaired cardiopulmonary reserve in an elderly population is related to postoperative morbidity and length of hospital stay after radical cystectomy. BJU International, 2013, 112, E13-9.	1.3	45
59	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 316-320.	0.9	5
60	Prognostic Risk Stratification of Patients with Urothelial Carcinoma of the Bladder with Recurrence After Radical Cystectomy. Journal of Urology, 2013, 189, 1275-1281.	0.2	51

#	Article	IF	Citations
61	In vivo and in vitro effects of RAD001 on bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1212-1221.	0.8	23
62	Manipulating the epigenome for the treatment of urological malignancies. , 2013, 138, 185-196.		17
63	The incidence of prostate cancer and urothelial cancer in the prostate in cystoprostatectomy specimens in a tertiary care Canadian centre. Canadian Urological Association Journal, 2013, 7, 35.	0.3	8
64	E-Cadherin and ï¿½-Catenin Expression during Urothelial Carcinogenesis Induced byN-butyl-N-(4-hydroxybutyl) nitrosamine in Mice. Urologia Internationalis, 2013, 91, 462-466.	0.6	4
65	Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. International Journal of Urology, 2013, 20, 866-871.	0.5	17
66	Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. BMC Urology, 2013, 13, 73.	0.6	12
67	Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer. Cancer Control, 2013, 20, 200-210.	0.7	22
68	New therapeutic targets in the management of urothelial carcinoma of the bladder. Research and Reports in Urology, 2013, 5, 53.	0.6	5
69	Perioperative chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 3, 223.	0.3	7
70	Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 2, 225.	0.3	2
71	The case for prostate capsule-sparing radical cystectomy in selected patients. Canadian Urological Association Journal, 2013, 3, 215.	0.3	4
72	CISTECTOMÃA RADICAL POR CÃNCER VESICAL EN UN HOSPITAL DOCENTE-ASISTENCIAL: ANÃLISIS DE RESULTADOS PERIOPERATORIOS. Revista Chilena De Cirugia, 2014, 66, 351-358.	0.1	0
73	Robot-Assisted Laparoscopic Radical Cystectomy. The Ewha Medical Journal, 2014, 37, 10.	0.1	0
74	The feasibility of radical cystectomy in elderly patients. Turk Uroloji Dergisi, 2014, 40, 9-14.	0.4	3
75	S117: Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. European Urology Supplements, 2014, 13, e1482.	0.1	0
76	Role of fluorodeoxyglucose positron emission tomography (<scp>FDG PET</scp>)â€computed tomography (<scp>CT</scp>) in the staging of bladder cancer. BJU International, 2014, 114, 389-395.	1.3	102
77	Local and systemic recurrence patterns of urothelial cancer after radical cystectomy. Kaohsiung Journal of Medical Sciences, 2014, 30, 504-509.	0.8	8
78	Robotic Surgery of the Bladder. , 2014, , .		2

#	Article	IF	Citations
79	Urinary functional outcomes in female neobladder patients. World Journal of Urology, 2014, 32, 221-228.	1.2	41
80	Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. World Journal of Surgical Oncology, 2014, 12, 14.	0.8	47
81	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 2014, 65, 778-792.	0.9	868
82	Effect of Alvimopan on Return of Bowel Function After Robot-Assisted Radical Cystectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2014, 24, 693-697.	0.5	21
84	Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Human Pathology, 2014, 45, 674-682.	1.1	49
85	Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 663-669.	0.8	22
86	Animal models of urinary bladder cancer and their application to novel drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 485-503.	2.5	12
87	Pelvic Irradiation and Its Effects on the Lower Urinary Tract: a Literature Review. Current Bladder Dysfunction Reports, 2015, 10, 295-302.	0.2	1
88	Perioperative chemotherapy for muscle invasive bladder cancer. Current Opinion in Supportive and Palliative Care, 2015, 9, 249-254.	0.5	1
89	Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. Journal of Surgical Oncology, 2015, 112, 427-429.	0.8	11
90	Long-term outcome of radical cystectomy â€“ metropolitan Australia experience. Journal of Clinical Urology, 2015, 8, 209-214.	0.1	1
91	Morphological and Functional Analysis of a Cohort of Patients Undergoing Orthotopic Ileal Neobladder. Urologia, 2015, 82, 164-167.	0.3	1
92	Immediate Radical Cystectomy for Massive Bleeding of Bladder Cancer. BioMed Research International, 2015, 2015, 1-4.	0.9	5
93	Robotic Partial Cystectomy for Primary Urachal Adenocarcinoma of the Urinary Bladder. Current Urology, 2015, 8, 183-188.	0.4	7
94	Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. International Journal of Oncology, 2015, 47, 377-383.	1.4	9
95	Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 731-742.	1.5	14
96	Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. International Urology and Nephrology, 2015, 47, 87-94.	0.6	75
97	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scandinavian Journal of Urology, 2015, 49, 453-462.	0.6	13

#	Article	IF	Citations
98	MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy. BMC Cancer, 2015, 15, 92.	1.1	24
99	Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. European Journal of Radiology, 2015, 84, 1023-1028.	1.2	27
100	[¹⁸F]Fluorodeoxyglucose â€“ positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scandinavian Journal of Urology, 2015, 49, 296-301.	0.6	27
101	Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy. BMC Urology, 2015, 15, 53.	0.6	19
102	Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. International Journal of Surgery, 2015, 13, 148-151.	1.1	22
103	Patients with an Orthotopic Low Pressure Bladder Substitute Enjoy Long-Term Good Function. Journal of Urology, 2016, 196, 1172-1180.	0.2	28
105	A Long Survival Case of Lateral Lymph Node Recurrence of Sigmoid Colon Cancer with Bladder Invasion Resected by Laparoscopic Surgery. Nihon Daicho Komonbyo Gakkai Zasshi, 2016, 69, 159-163.	0.1	2
106	Sequential bacillus Calmette-GuÃ©rin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. Journal of Urology, 2016, 195, 1697-1703.	0.2	33
107	Studer Orthotopic Neobladder: A Modified Surgical Technique. Urology, 2016, 88, 222-225.	0.5	10
108	A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). European Urology, 2016, 69, 613-621.	0.9	246
109	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Urology, 2017, 71, 462-475.	0.9	1,241
110	Lymphocyteâ€toâ€monocyte ratio and neutrophilâ€toâ€lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. Journal of Surgical Oncology, 2017, 115, 455-461.	0.8	46
111	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. Urology Practice, 2017, 4, 388-394.	0.2	2
112	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 2017, 71, 961-969.	0.9	154
113	Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 457.e15-457.e21.	0.8	18
114	Chronic kidney disease as a risk factor for recurrence and progression in patients with primary nonâ€muscleâ€invasive bladder cancer. International Journal of Urology, 2017, 24, 594-600.	0.5	8
115	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Scientific Reports, 2017, 7, 5554.	1.6	73
116	Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer. Npj Genomic Medicine, 2017, 2, 36.	1.7	105

#	Article	IF	Citations
117	Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism. Oncology Letters, 2017, 14, 241-249.	0.8	27
118	Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials. Future Oncology, 2017, 13, 1195-1204.	1.1	3
119	Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. World Journal of Urology, 2017, 35, 921-927.	1.2	14
120	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362.	0.9	31
123	Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy. Journal of Cancer, 2017, 8, 3567-3574.	1.2	16
125	Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies. Cellular Physiology and Biochemistry, 2018, 46, 1352-1364.	1.1	25
126	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta OncolÃ³gica, 2018, 57, 491-497.	0.8	22
127	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. Methods in Molecular Biology, 2018, 1655, 251-273.	0.4	6
129	A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 43-53.	0.8	113
130	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology, 2018, 36, 215-220.	1.2	71
131	Intravoxel incoherent motion diffusionâ€weighted imaging in assessing bladder cancer invasiveness and cell proliferation. Journal of Magnetic Resonance Imaging, 2018, 47, 1054-1060.	1.9	20
132	Open Techniques and Extent (Including Pelvic Lymphadenectomy). , 2018, , 369-437.		0
134	Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma. Cancer Management and Research, 2018, Volume 10, 503-511.	0.9	4
135	Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 258-266.	0.7	3
137	BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1. International Journal of Molecular Sciences, 2018, 19, 1116.	1.8	26
138	Utility of intravoxel incoherent motion MRI derived parameters for prediction of aggressiveness in urothelial bladder carcinoma. Journal of Magnetic Resonance Imaging, 2018, 48, 1648-1656.	1.9	5
139	Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?. Translational Andrology and Urology, 2019, 8, S280-S282.	0.6	1
140	EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/Î²-catenin signaling pathway in human bladder cancer. International Journal of Biological Sciences, 2019, 15, 2139-2155.	2.6	42

#	Article	IF	Citations
141	Neoadjuvant therapy in urothelial cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 329-333.	0.3	1
143	Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. BMC Urology, 2019, 19, 10.	0.6	42
144	Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems. Drug Development Research, 2019, 80, 404-424.	1.4	131
145	Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 791-799.	0.8	30
146	Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 810.e7-810.e15.	0.8	22
147	Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. Urology, 2019, 130, 93-98.	0.5	18
148	Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?. Scandinavian Journal of Urology, 2019, 53, 45-50.	0.6	4
149	The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study. BMC Urology, 2019, 19, 117.	0.6	3
150	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). Clinical and Translational Oncology, 2019, 21, 64-74.	1.2	16
151	The deregulation of miR-133b is associated with poor prognosis in bladder cancer. Pathology Research and Practice, 2019, 215, 354-357.	1.0	7
152	A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 811-820.	1.2	7
153	ARPC4 promotes bladder cancer cell invasion and is associated with lymph node metastasis. Journal of Cellular Biochemistry, 2020, 121, 231-243.	1.2	17
154	Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer. Pathology and Oncology Research, 2020, 26, 253-261.	0.9	4
155	National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004â€“2013. European Urology Oncology, 2020, 3, 343-350.	2.6	6
156	STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. Pathology and Oncology Research, 2020, 26, 1243-1249.	0.9	10
157	Tumourâ€associated B cells in urothelial urinary bladder cancer. Scandinavian Journal of Immunology, 2020, 91, e12830.	1.3	25
158	Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 935.e9-935.e16.	0.8	2
159	Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor. Anticancer Research, 2020, 40, 4299-4307.	0.5	7

#	Article	IF	Citations
160	Risk Factors for Urethral Recurrence in Men After Radical Cystectomy with Orthotopic Urinary Diversion for Urothelial Carcinoma: A Retrospective Cohort Study . Cancer Management and Research, 2020, Volume 12, 6739-6746.	0.9	2
161	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. Current Opinion in Urology, 2020, 30, 547-556.	0.9	12
162	Role and efficacy of current biomarkers in bladder cancer. AME Medical Journal, 0, 5, 6-6.	0.4	7
163	Guar bean in urinary cytology: a morphologic pitfall. Journal of the American Society of Cytopathology, 2021, 10, 41-46.	0.2	4
166	Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matcheda€pair analysis in a multicenter cohort. International Journal of Urology, 2021, 28, 656-664.	0.5	8
167	Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 2800.	1.8	19
168	Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 159, 103235.	2.0	7
169	Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy. Cancers, 2021, 13, 1748.	1.7	6
170	Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review. Translational Andrology and Urology, 2021, 10, 1865-1877.	0.6	7
171	Design, manufacturing and applications of small-scale magnetic soft robots. Extreme Mechanics Letters, 2021, 44, 101268.	2.0	44
172	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers, 2021, 13, 2548.	1.7	17
173	Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nature Communications, 2021, 12, 2776.	5.8	92
174	Surgery for Bladder and Upper Tract Urothelial Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 543-566.	0.9	4
175	Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 368.e11-368.e17.	0.8	7
176	Robot-Assisted Intracorporeal Ileal Conduit. , 2014, , 111-116.		2
177	Chemotherapy for Metastatic Bladder Cancer. , 2011, , 409-431.		2
178	Piceatannol inhibits proliferation and induces apoptosis of bladder cancer cells through regulation of the PTEN/AKT signal pathway. Cellular and Molecular Biology, 2020, 66, 181-184.	0.3	2
179	Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival. Oncotarget, 2016, 7, 75648-75658.	0.8	10

#	Article	IF	Citations
180	AMPK activation-dependent autophagy compromises oleanolic acid-induced cytotoxicity in human bladder cancer cells. Oncotarget, 2017, 8, 67942-67954.	0.8	21
181	Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. Oncotarget, 2016, 7, 6424-6435.	0.8	22
182	Radical cystectomy: a review of techniques, developments and controversies. Translational Andrology and Urology, 2020, 9, 3073-3081.	0.6	16
183	Bladder Cancer: Innovative Approaches Beyond the Diagnosis. Current Medicinal Chemistry, 2014, 21, 2219-2236.	1.2	9
184	Radical cystectomy for bladder cancer: early and late postoperative complications. Urology Herald, 2019, 7, 24-50.	0.1	4
185	Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Cancer Research and Treatment, 2016, 48, 1084-1091.	1.3	15
186	Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, TC01-5.	0.8	19
187	Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance. Frontiers in Endocrinology, 2021, 12, 684140.	1.5	4
189	Molecular Nomograms for Predicting Prognosis and Treatment Response. , 2011, , 165-191.		0
190	Chemotherapeutic Agents for Urologic Oncology. , 2011, , 175-186.		2
191	Step-by-Step Approach to Robotic Cystectomy and Intracorporeal Urinary Diversion. , 2011, , 369-380.		0
194	Robot-Assisted Radical Cystectomy as a Treatment Modality for Patients with Muscle-Invasive Bladder Cancer. , 0, , .		0
195	Postoperative Radiotherapy in Bladder Cancer Patients: 5-Year Institutional Experience of National Cancer Institute, Cairo University. Journal of Cancer Therapy, 2015, 06, 579-593.	0.1	0
196	The role of robotic partial cystectomy in a patient with metastatic primary adenocarcinoma of the bladder. International Journal of Cancer Therapy and Oncology, 2015, 3, 030120.	0.2	1
197	The Immediate Results of Surgical Treatment of Bladder Cancer. International Journal of Biomedicine, 2016, 6, 110-113.	0.1	0
198	Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma. Oncotarget, 2017, 8, 89228-89235.	0.8	1
199	Minimally Invasive Radical Cystectomy and Its Role and Future in Treatment of Bladder Cancer Patients. Myth or Reality?. , 2018, , 65-74.		0
200	Is There Still a Role for Radical Cystectomy?. , 2018, , 55-64.		0

#	Article	IF	Citations
201	High-soluble CGA levels are associated with poor survival in bladder cancer. Endocrine Connections, 2019, 8, 625-633.	0.8	1
202	Đ¢Ñ€Đ¸Đ¼Đ¾ĐĐ°Đ»ÑŒĐ½Đ° Đ¾Ñ€Đ³Đ°Đ½Đ¾Đ·Đ±ĐµÑ€Ñ–Đ³Đ°ÑŽÑ‡Đ° Ñ‚ĐµÑ€Đ°Đ¿Ñ–Ñ•Đ² ÑÑƒÑ‡Đ°Ñ•Đ½Đ¾Đ¼Ñƒ Đ°Đ		
203	Detection of Incidental Prostate Cancer or Urothelial Carcinoma Extension in Urinary Bladder Cancer Patients by Using Multiparametric MRI: A Retrospective Study Using Prostate Imaging Reporting and Data System Version 2.0. Journal of the Korean Society of Radiology, 2020, 81, 610.	0.1	0
204	Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy. Translational Andrology and Urology, 2020, 9, 1270-1277.	0.6	1
205	Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?. Current Drug Targets, 2020, 22, 14-21.	1.0	4
206	Mortality after radical cystectomy is strongly related to the institution's volume of surgeries. Einstein (Sao Paulo, Brazil), 2020, 18, eAO5628.	0.3	4
207	Impact of clinical stage on the outcome of laparoscopic radical cystectomy: a prospective cohort study. African Journal of Urology, 2020, 26, .	0.1	1
208	Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Research, 2012, 32, 733-8.	0.5	23
209	Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical cystoprostatectomy for men with bladder urothelial carcinoma. American Journal of Clinical and Experimental Urology, 2014, 2, 156-60.	0.4	2
210	Robot-assisted full-thickness cystectomy for malignant bladder tumors. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 63.	0.0	0
211	Adenocarcinoma de prÃ³stata como hallazgo incidental en cistoprostatectomÃa radical.. , 2020, 8, 29-31.		0
212	A Case of Sigmoid Colon Cancer with a Solitary Metastasis to the Left Obturator Lymph Nodes. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2021, 82, 1396-1400.	0.0	0
213	Surgical management of urinary diversion and stomas in adults: multidisciplinary Italian panel guidelines. Minerva Urology and Nephrology, 2022, 74, .	1.3	2
214	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. Journal of Clinical Medicine, 2022, 11, 497.	1.0	3
215	piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers. Biomolecules, 2022, 12, 186.	1.8	8
216	Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	4
217	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer. Genes, 2022, 13, 422.	1.0	2
218	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22

#	Article	IF	Citations
219	Conditional survival of trimodal therapy for nonmetastatic muscleâ€invasive bladder cancer: A <scp>SEER</scp> database analysis. Cancer Medicine, 2022, 11, 2356-2365.	1.3	5
220	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancerâ€"A Review. Cancers, 2022, 14, 38.	1.7	16
221	The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance. Clinical Genitourinary Cancer, 2021, , .	0.9	3
222	Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric stricture. Langenbeck's Archives of Surgery, 2022, 407, 1233-1240.	0.8	3
223	Mechanistic analysis of resistance to REIC/Dkk-3-induced apoptosis in human bladder cancer cells. Acta Medica Okayama, 2008, 62, 393-401.	0.1	4
224	Increased NUSAP1 expression is associated with lymph node metastasis and survival prognosis in bladder urothelial carcinoma. Scientific Reports, 2022, 12, 7003.	1.6	1
225	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	0.4	2
226	Update of the Diagnostic and Therapeutic Role of the Pelvic Lymph Node Dissection Boundaries During Radical Cystectomy in Muscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2022, 20, 71-81.	0.1	0
227	Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer. Oncogene, 2022, 41, 3587-3598.	2.6	8
228	The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer. BJU International, 2023, 131, 244-252.	1.3	1
229	Urodynamic assessment of orthotopic urinary diversions. Frontiers in Urology, 0, 2, .	0.2	0
230	Phase 1 Study of Chemoradiotherapy Combined with NivolumabÂÂ±ÂIpilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. European Urology, 2022, 82, 518-526.	0.9	12
231	Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	5
232	Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer. Cancer Medicine, 2023, 12, 5222-5232.	1.3	6
233	Integrated molecular analyses of an interferon-Î³ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. Heliyon, 2022, 8, e12102.	1.4	0
234	Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 15970.	1.8	9
235	The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy. Medicine (United States), 2022, 101, e31973.	0.4	0
236	Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer. Translational Andrology and Urology, 2023, 12, 176-186.	0.6	1

#	Article	IF	Citations
237	Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation. Cancers, 2023, 15, 1886.	1.7	2
238	Ileal Conduit Versus Orthotopic Neobladder Urinary Diversion in Robot-assisted Radical Cystectomy: Results from a Multi-institutional Series. European Urology Open Science, 2023, 50, 47-56.	0.2	3
239	Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis. Journal of Cancer Research and Therapeutics, 2022, 18, 1884.	0.3	4
240	Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. Cancers, 2023, 15, 1323.	1.7	1
242	EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial. BMJ Open, 2023, 13, e071304.	0.8	4
243	The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. European Medical Journal Urology, 0, , 88-93.	0.0	0